Kopruszinski CM, Thornton P, Arnold J, Newton P, et al. Characterization and preclinical evaluation of a protease activated receptor 2 (PAR2) monoclonal antibody as a preventive therapy for migraine. Cephalalgia 2020 Nov 1:333102420966581. doi: 10.1177/0333102420966581.
PMID: 33131305